Yutaka Niihara Acquires 31,100 Shares of Emmaus Life Sciences (NASDAQ:EMMA) Stock

Emmaus Life Sciences (NASDAQ:EMMA) CEO Yutaka Niihara purchased 31,100 shares of Emmaus Life Sciences stock in a transaction dated Wednesday, February 12th. The stock was bought at an average price of $1.75 per share, with a total value of $54,425.00.

Yutaka Niihara also recently made the following trade(s):

  • On Friday, February 7th, Yutaka Niihara purchased 18,800 shares of Emmaus Life Sciences stock. The stock was bought at an average price of $1.70 per share, with a total value of $31,960.00.

Shares of NASDAQ EMMA opened at $2.77 on Friday. The stock has a market cap of $134.27 million, a PE ratio of -0.25 and a beta of 2.91. Emmaus Life Sciences has a fifty-two week low of $0.95 and a fifty-two week high of $11.76. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.44 and a current ratio of 1.44. The stock has a fifty day moving average of $2.40 and a 200-day moving average of $2.90.

Emmaus Life Sciences (NASDAQ:EMMA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.60) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.24. The company had revenue of $6.08 million during the quarter, compared to analysts’ expectations of $0.87 million. Emmaus Life Sciences had a negative return on equity of 511.05% and a negative net margin of 489.28%. On average, sell-side analysts predict that Emmaus Life Sciences will post -5.57 EPS for the current year.

Separately, Zacks Investment Research upgraded Emmaus Life Sciences from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research report on Tuesday, November 5th.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement.

Featured Story: Cryptocurrencies

Insider Buying and Selling by Quarter for Emmaus Life Sciences (NASDAQ:EMMA)

Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.